|
HANALL BIOPHARMA is a South Korean pharmaceutical company established in 1973 that develops and manufactures synthetic and biopharmaceutical products. The company's commercial portfolio includes probiotics, treatments for prostate cancer and central precocious puberty, non-absorbable antibiotics, and hair loss therapies, with key products including Biotop, Eliga, Norimix, and Hairgro. Its research and development focus targets autoimmune diseases, ocular disorders, and neurological conditions, featuring pipeline candidates such as batoclimab, aimeroferubart, tanfanercept, and HL192. HANALL BIOPHARMA operates through its subsidiary HPI, Inc. for overseas clinical trials and licensing, and maintains partnerships with Immunovant, Harbour BioMed, NurrOn Pharmaceuticals, and Daewoong Pharmaceutical for the development and commercialization of its novel therapeutics. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage hanall.com |
| Sector Healthcare | IR page — | |
|
Tags
autoimmune diseases, ocular disorders, neurological diseases, probiotics, prostate cancer, hair loss, antibiotics, monoclonal antibodies, fcrn inhibitors, tnf inhibitors, parkinson's disease, dry eye disease, Biotop, Eliga, Norimix, Hairgro, HPI Inc., HanAll Pharmaceutical International Inc., batoclimab, HL161BKN, aimeroferubart, HL161ANS, Immunovant, Harbour BioMed, CSPC Pharmaceutical Group, NurrOn Pharmaceuticals, Daewoong Pharmaceutical, HL192, ATH-399A, tanfanercept, HL036, Turn Biotech
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 2.287T |
| Market cap (USD) | $ 1.683B |
| P/E | -89.34 |
| PEG | — |
| P/BV | 14.15 |
| P/S | 14.06 |
| P/OCF | -239.75 |
| P/FCF | -695.45 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -3.4% |
| ROI | -3.4% |
| ROIC | -0.42% |
| Profit margin | -3.6% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -47.1% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155.185B | 138.944B | 134.91B | 109.995B | 101.594B | 88.602B | 108.452B | 91.839B | 84.231B | 82.882B | 80.023B | 80.88B | 74.228B |
| Net profit | -5.559B | -1.805B | 3.509B | 251.474M | 8.896B | 19.764B | 19.174B | 3.3B | 5.813B | 2.026B | -7.077B | -12.658B | -21.499B |
| Free cash flow | -3.288B | — | — | — | — | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 22.7B | 19.1B | 17.5B | 22.6B | 15.7B | 15.6B | 30.7B | 22.5B | 20.1B | 19.4B |
| ↳ YoY growth | -3.6% | -15.7% | -8.3% | +29.2% | -30.5% | -1.1% | +97.4% | -26.7% | -10.9% | -3.6% |
| ↳ 5y CAGR | -5.6% | -4.9% | -7.7% | -7.3% | +10.0% | +5.2% | -2.4% | +4.2% | ||
| Borrowings, current (KRW) | — | — | — | — | — | — | — | 0.00 | 0.00 | 15.7B |
| Borrowings, non-current (KRW) | — | — | — | — | — | — | — | 0.00 | 0.00 | 15B |
| Lease liabilities (KRW) | — | — | — | 568M | 552M | 1.34B | 1.31B | 1.29B | 1.45B | 1.18B |
| Cash and deposits (KRW) | 9.5B | 41.9B | 22.7B | 6.12B | 4.2B | 12.8B | 16.8B | 33.7B | 16.4B | 24.7B |
| Intangible assets (KRW) | 11.7B | 10.2B | 5.52B | 10.7B | 15.1B | 19.1B | 23.8B | 32.6B | 51.8B | 64.6B |
| Right-of-use assets (KRW) | — | — | — | 563M | 539M | 1.31B | 1.4B | 1.35B | 1.5B | 1.2B |
| Net debt (borrowings + leases - cash) (KRW) | — | — | — | — | — | — | — | -32.4B | -14.9B | 7.17B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 3.95B | 42.1B | -2.99B | 20.5B | 929M | 840M | 25.3B | 29.6B | 9.36B | -2.34B |
| Purchases of property, plant and equipment (KRW) | — | — | — | — | — | — | — | -2.41B | -1.64B | -948M |
| Purchases of intangible assets (KRW) | -1.04B | -481M | — | -6.11B | -4.81B | -4.4B | -4.77B | -6.79B | -18.7B | -13.2B |
| Share buybacks (cash effect) (KRW) | — | — | — | — | — | — | -10B | 0.00 | 0.00 | -3.22B |
| Interest paid (cash effect) (KRW) | — | — | — | — | — | — | -39.5M | -63.9M | -71M | -134M |
| Income taxes paid (cash effect) (KRW) | -228M | 66.4M | -1.18B | -1.91B | -1.83B | -1.7B | -607M | -1.02B | -782M | 215M |
| Free cash flow (OCF - PPE - intangibles) (KRW) | — | — | — | — | — | — | — | 20.4B | -13.7B | -16.5B |
| Income detail | ||||||||||
| Research and development expense (KRW) | — | — | — | — | — | — | — | 23.9B | 20B | 19.3B |
| Total comprehensive income (KRW) | 2.24B | 6.3B | 5.16B | 23B | 39.9B | -19.6B | 12.8B | 15.5B | -19.9B | -6.19B |
| Comprehensive income to owners (KRW) | 2.24B | 6.3B | 5.16B | 23B | 39.9B | -19.6B | 12.8B | 15.5B | -19.9B | -6.19B |
| Reported | Mar 30, 2018 | Mar 30, 2018 | Apr 1, 2019 | Mar 30, 2020 | Mar 18, 2021 | Mar 20, 2024 | Mar 20, 2024 | Mar 18, 2026 | Mar 18, 2026 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding HANALL BIOPHARMA
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.